Anoscopy Genius
AI for anal cancer precursor lesion detection in high-resolution anoscopy
Software · OtherCompany source
Company profile
About Digestaid - Artificial Intelligence Development
DigestAID is an enterprise focused on developing artificial intelligence solutions for multiple fields of digestive endoscopy. The company's mission is to overcome diagnostic limitations of endoscopic methods by delivering faster and more accurate diagnoses through innovative AI solutions. DigestAID offers a comprehensive portfolio of AI technologies spanning non-invasive capsule endoscopy, live vision technologies for cholangioscopy and endoscopic ultrasound, high-resolution anoscopy, device-assisted enteroscopy, and digestive motility analysis including anorectal and esophageal manometry. The company has processed over 100,000 digital digestive exams and achieved greater than 90% global diagnostic accuracy. With a dataset of over 2 million exams from world-renowned institutions, DigestAID has produced 200+ publications in peer-reviewed journals and scientific meetings. The team combines experienced gastroenterologists with skilled data engineers to develop market-disrupting AI solutions. DigestAID holds patent-pending technology including DeepCapsule, which has received approved patent rights for 20 years. The company serves healthcare providers and institutions globally, focusing on precision medicine in digestive endoscopy and management of big data in digestive pathology.
Company description Digestaid - Artificial Intelligence Development official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Work at Digestaid - Artificial Intelligence Development?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- anal squamous cell carcinoma precursor lesions
- anorectal motility disorders
- biliary strictures
- cholangiocarcinoma
- Crohn's disease
- digestive lesions
- erosions
- esophageal motility disorders
- hemorrhagic lesions
- IBD
- pancreatic cysts
- ulcers
Who it serves
- Endoscopy centers
- Gastroenterology departments
- Healthcare providers
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsBrazil · Global · Portugal · Spain
Company sourceOfficial website
Company milestones
Platform expansion
DeepCapsule patent approved with 20-year rights. Currently undergoing clinical validation. 8 patent applications filed. Partnerships established with world-leading healthcare institutions.
Partnerships
Recorded partners
- World leading healthcare institutions
- World-renowned healthcare institutions
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Deep Bowel
AI solution for device-assisted enteroscopy lesion detection
Software · OtherCompany source
Deep Capsule
AI solution for capsule endoscopy lesion detection and differentiation
Software · OtherCompany source
GI Spy
Panendoscopic AI solution for colon capsule endoscopy
Software · OtherCompany source
IBD Smart
AI solution for Crohn's disease capsule endoscopy
Software · OtherCompany source
Smart Cholangio
AI for biliary stricture detection and cholangiocarcinoma diagnosis
Software · OtherCompany source
Smart Esophagus
Automatic esophageal manometry classification per Chicago 4.0
Software · OtherCompany source
Smart Mano
First AI platform for anorectal manometry pattern detection
Software · OtherCompany source
Smart Pancreas
AI for pancreatic cyst detection and classification via EUS
Software · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Correction: Saraiva et al. Deep Learning and High-Resolution Anoscopy: Development of an Interoperable Algorithm for the Detection and Differentiation of Anal Squamous Cell Carcinoma Precursors-A Multicentric Study. Cancers 2024, 16, 1909.Cancers · Nov 19, 2025
Deep Learning and High-Resolution Anoscopy: Development of an Interoperable Algorithm for the Detection and Differentiation of Anal Squamous Cell Carcinoma Precursors-A Multicentric Study.Cancers · May 17, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Deep Capsule® (Deep Capsule US)K250655 · 510k · Mar 12, 2026
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Global diagnostic accuracy
>90% across digestive lesion detection
Exams processed
100,000+ digital digestive exams analyzed
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Miguel Mascarenhas
CEO
Guilherme Macedo
Medical R&D Chairman
Hélder Cardoso
CMO
Tiago Andrade
President, Board of Directors
André Santos
Chief Medical Software Officer
Francisca Pinheiro
R&D COO/VP to the CEO
Bruno Silva
Product COO
João Ferreira
Head of AI
06 · Company updates
Updates from Digestaid - Artificial Intelligence Development
Recent articles published on Digestaid - Artificial Intelligence Development's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.